Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Avian influenza
Avian influenza
Avian influenza
Drug discovery
1
drug
With orphan designation
Rare infectious diseases
Avian influenza
Overview
Avian influenza (bird flu) is caused by influenza A viruses (primarily H5N1) that circulate globally in wild birds and sporadically infect mammals, including humans. Transmission occurs through direct contact with infected animals or contaminated environments. High-risk populations include poultry/dairy workers and veterinarians. Symptoms range from mild conjunctivitis to severe pneumonia and ARDS. Early antiviral treatment (≤48 hr) improves outcomes. While human-to-human transmission remains rare, case fatality rates exceed 50% for H5N1 without treatment [1][7][9][13][17].
Burden
Mortality: 54% CFR in Western Pacific H5N1 cases (2003-2024) [8], 40-52% for H7N9 [17].
Economic: $3B USD losses in 2022-2024 US poultry culls [6][15].
Emerging Threats: Multispecies spread (cows, seals) since 2024 with 50+ human cases, though current human cases remain mild with treatment [4][15][19].
Categories: rare infectious diseases, rare respiratory diseases
Research Papers
4,614 drug discovery papers about Avian influenza, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:
4,614 drug discovery papers about Avian influenza, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
antibodies
2026-09-30 | Highly Pathogenic Avian Influenza Virus Subtype 5 in Cetaceans, Brazil.
We identified highly pathogenic avian influenza virus subtype H5 in stranded dolphins along the coastline of Brazil during 2023-2025. Infected animals included species classified as vulnerable or endangered. Our results highlight the need for ongoing surveillance of cetaceans susceptible to viral infections, which pose an additional threat to threatened species.
2026-09-18 | H5N1 clade 2.3.2.1e lineage transition in Lao PDR during 2023-2024 associated with regional spread and human infection risk-associated receptor-binding features.
Highly pathogenic avian influenza (HPAI) H5N1 viruses clade 2.3.2.1e has re-emerged in the Indochinese Peninsula, raising concerns about regional spread and zoonotic risk. We characterized eight H5N1 viruses isolated from 32 environmental and poultry-derived samples collected in Lao People's Democratic Republic (Lao PDR) live bird markets during 2023-2024. Whole-genome and phylogenetic analyses showed that all isolates belonged to clade 2.3.2.1e and were distinct from the previously dominant Lao clade 2.3.2.1c, indicating lineage transition in poultry-associated viruses. The Lao isolates were distributed across regional sublineages rather than forming a single local cluster, suggesting repeated introductions and cross-border genetic connectivity. Segment-level nucleotide identities ranged from 97.2 to 99.9%, revealing a complex mosaic genotype constellation. All isolates retained the avian-associated glutamic acid residue at position 627 of polymerase basic protein 2 (PB2-627E) and the aspartic acid residue at position 701 of polymerase basic protein 2 (PB2-701D). Hemagglutinin (HA) analysis showed a conserved polybasic cleavage motif, PQRERRRKRGLF, and conserved HA1-123S, HA1-154N, HA1-263T, and HA2-497L, whereas isolate-level variation was observed at HA1-94, HA1-188, and HA1-223. Structural modeling and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) analysis of a representative isolate further highlighted receptor binding site (RBS) associated HA features. Importantly, RBS-associated HA variation was detected despite the absence of lysine residue at position 627 of polymerase basic protein 2 (PB2-627 K), suggesting that early molecular changes relevant to mammalian or human adaptation may arise before acquisition of canonical mammalian-adaptive polymerase mutations. These findings support sustained cross-border genomic surveillance and receptor-binding-focused characterization of H5N1 viruses circulating in Lao live bird markets.
2026-09-16 | Experimental Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Alpacas, 2026.
Highly pathogenic avian influenza (HPAI) A(H5N1) clade 2.3.4.4b virus continues to spread globally and sporadically transmits from avian reservoirs to mammalian hosts. In May 2024, H5N1 infections in young goats and alpacas in the United States were reported. Nevertheless, the overall susceptibility of camelids to clade 2.3.4.4b virus remains unclear. We conducted a controlled experimental infection study in 6 alpacas, assessing clinical signs, viral shedding, tissue distribution, and serologic responses after intranasal inoculation with HPAI H5N1 genotype B3.13 virus. Observed illness was generally mild; body temperature increased slightly and food intake reduced for up to 3 days postinfection. We detected viral RNA in nasal swab samples and confirmed infectious HPAI H5N1 virus. Immunohistochemistry and RNA in situ hybridization detected virus only in the nasopharyngeal tonsil and nasal conchae at 4 days postinfection. Our findings suggest alpacas are susceptible to productive H5N1 infection, highlighting implications for livestock surveillance and biosecurity in regions with ongoing circulation.
2026-09-15 | Enhanced induction of inflammatory cytokines in human lung cells infected with highly pathogenic recent H5N1/2024 avian influenza virus.
Highly pathogenic (HP) H5N1 avian influenza viruses are zoonotic pathogens and are endemic in wild birds and poultry around the world. Pro-inflammatory cytokines are supposed to contribute to the severe clinical symptoms in infected animals and humans. In this study, we determined the infectivity and cytokine induction in primary human lung cells infected with HP H5N1 avian influenza viruses and seasonal H3N2 influenza viruses. MDCK cells were used to measure viral titers in the supernatants of infected human lung cells by log10TCID50/ml. Quantitative real-time PCR was used to detect the induction of cytokine genes using mRNA from the infected primary human lung cells. HP H5N1 avian influenza viruses induced higher viral titers than seasonal H3N2 influenza viruses in supernatants of primary human lung cells. In addition, HP H5N1avian influenza viruses induced the genes of pro-inflammatory cytokines such as IL-23, IL-1α, IL-1β, IL-6, and IL-8 at significantly higher levels than seasonal H3N2 influenza viruses in primary human lung cells. Our data suggest that the high viral replication and the high induction of pro-inflammatory cytokines in the human lung cells infected with HP H5N1 avian influenza viruses may enhance pathogenicity in the infected humans as compared to seasonal H3N2 influenza viruses.
2026-09-14 | Genomic detection of highly pathogenic avian influenza H5N1 in Antarctic seabirds reveals connectivity with South American viral lineages.
Emerging avian viruses increasingly threaten Antarctic wildlife, raising concerns about ecosystem health and biodiversity. In this study, we conducted a comprehensive investigation of avian influenza virus (influenza A virus, IAV) in both resident and migratory birds inhabiting the South Shetland Islands, Antarctica. During the 2024-2025 austral summer, 278 samples were collected and screened using real-time RT-PCR targeting the IAV M gene. IAV RNA was detected in 30 samples, and eight of these were found to be positive for H5. Complete genome sequencing was performed on samples from a gentoo penguin (Pygoscelis papua) and a southern giant petrel (Macronectes giganteus), revealing the presence of highly pathogenic avian influenza virus H5N1, clade 2.3.4.4b. Phylogenetic analysis demonstrated that these viral genomes closely cluster with contemporary South American strains, indicating a direct connectivity between Antarctic seabirds and the broader H5N1 transmission network. Our findings highlight the heightened vulnerability of Antarctic ecosystems to emerging infectious diseases and emphasize the critical need for sustained genomic surveillance. These efforts are essential to monitor wildlife health, inform conservation strategies, and implement effective biosecurity measures to safeguard Antarctic biodiversity.
small molecules
2026-09-30 | Baloxavir-Based Combination Therapy for Protection against Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Mice.
Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus continues to cause animal outbreaks and sporadic zoonotic infections. In a mouse model of lethal influenza disease, we compared oseltamivir, baloxavir, and molnupiravir monotherapies with 2-drug combinations. Baloxavir-based combinations improved survival, reduced lung viral loads, and prevented extrapulmonary dissemination, supporting H5N1 preparedness strategies.
2026-09-16 | In silico evaluation of selected plant-based compounds as potent dual target inhibitors against highly pathogenic avian influenza H5N1 virus.
1. Influenza viruses remain a serious global health issue due to their high morbidity and mortality rates. Among them, avian influenza H5N1 virus is highly pathogenic, causing up to 100% mortality in poultry. As the avian influenza H5N1 virus continues to mutate across different regions, understanding multiple viral proteins, particularly the mutated haemagglutinin (HA) and neuraminidase (NA), is crucial for effective control.2. In this study, dual-target inhibitors capable of neutralising both HA and NA were developed, and a comprehensive in silico analysis was performed on different variants collected over the past decade. Structural modelling revealed conserved domains in NA (A0A1I9QM14, China) and HA (A0A0A0V4U2, Bali), which were selected for ligand docking.3. Twenty active compounds, traditionally used as natural feed additives in broiler chicken diets, were screened using protein-ligand docking, ADME profiling, and molecular dynamics (MD) simulations. Quercetin and luteolin emerged as promising dual-target inhibitors, showing high binding affinity, drug-likeness, and favourable toxicity profiles. The binding free energy (ΔG = -8 ± 0.2 kcal/mol) from docking studies confirmed their inhibitory potential against avian influenza H5N1 virus HA and NA.4. The results demonstrated that virtual screening of natural compounds can effectively identify those effective against influenza virus surface proteins. This integrative computational-experimental strategy supported the development of novel plant-derived antiviral agents with potential applications for disease control.
2026-08-25 | Hypoxia-inducible factor 1-alpha inhibition mitigates inflammatory responses induced by H9N2 avian influenza virus.
H9N2 avian influenza virus (AIV) poses significant threats to poultry and public health, with the potential to contribute to the emergence of more virulent influenza strains. Hypoxia-inducible factor 1-alpha (HIF-1α) plays a crucial role in viral pathogenesis, immune regulation, and inflammation, making it a promising target for therapeutic intervention. Here, we explored the involvement of HIF-1α in H9N2 AIV pathogenesis and associated inflammatory responses. Our data revealed that HIF-1α exacerbates inflammation induced by H9N2 AIV infection through its regulation of mitochondrial fitness. Additionally, we investigated Sotetsuflavone (Seo), a naturally derived flavonoid, for its potential to modulate inflammatory responses following H9N2 infection. Molecular docking coupled with surface plasmon resonance assays indicated that Seo exhibits robust binding affinity to HIF-1α, implying a direct inhibitory mechanism. Subsequent in vitro studies demonstrated that Seo greatly reduced the production of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, through suppressing the HIF-1α signaling pathway in HD11 cells infected with H9N2 AIV. Correspondingly, in vivo experiments established that Seo administration significantly ameliorated pulmonary inflammation in H9N2-infected mice, while also enhancing alveolar epithelial repair, as evidenced by increased expression of type II alveolar epithelial cell markers Abca3 and Sftpb. Collectively, these findings identify Seo as a potent inhibitor of HIF-1α, highlighting its therapeutic potential in mitigating inflammation and lung damage associated with influenza virus infection.IMPORTANCEH9N2 avian influenza virus triggers inflammatory lung injury via hypoxia-inducible factor-1 alpha (HIF-1α)-mediated dysregulation of mitochondrial function. The natural flavonoid Sotetsuflavone (Seo) directly binds and inhibits HIF-1α, as confirmed by molecular docking and surface plasmon resonance assays. In H9N2-infected HD11 cells, Seo suppresses HIF-1α signaling, reducing IL-1β, IL-6, and TNF-α production. In vivo, Seo treatment attenuates pulmonary inflammation and enhances alveolar epithelial repair in mice, upregulating type II pneumocyte markers (Abca3 and Sftpb). These findings identify Seo as a promising HIF-1α-targeted therapeutic for influenza-associated immunopathology.
2026-08-22 | Galectin-3 exacerbates influenza a virus pathogenesis via dual mechanisms: Promoting hemagglutinin-dependent entry and driving nlrp3 inflammasome activation.
Influenza A viruses (IAVs), particularly highly pathogenic avian influenza (HPAI) strains like H5N1 and H7N9, cause severe pneumonia and acute respiratory distress syndrome (ARDS) driven by dysregulated cytokine storms. A key mediator of this immunopathology is the excessive activation of the NLRP3 inflammasome, which governs the maturation of IL-1β. Galectin-3 (Gal3), a β-galactoside-binding lectin, is upregulated during infection; however, its specific regulatory role in coordinating NLRP3 inflammasome activation across distinct viral hemagglutinin (HA) subtypes remains to be elucidated. In this study, we demonstrate that Gal3 functions as a critical amplifier of influenza pathogenesis through a distinct dual-stage mechanism. Results from viral binding and internalization assays indicate that extracellular Gal3 promotes viral entry by interacting with viral HA, an effect that is strictly strain-dependent (H5N1 > H1N1 > H7N9). This enhanced entry consequently amplifies the initial signal for inflammasome activation. Intracellularly, Gal3 regulates the NLRP3 cascade by sustaining NF-κB activation (priming) to upregulate NLRP3 and pro-IL-1β transcription and acting as a facilitator to strengthen the NLRP3-ASC-pro-caspase-1 interaction, promoting ASC oligomerization (activation). Consistently, in vivo studies demonstrate that Gal3-deficient mice exhibit significantly improved survival, reduced weight loss, and attenuated pulmonary inflammation and IL-1β release following infection, with the most pronounced protective effects observed against H5N1. Collectively, these findings identify Gal3 as a potent host factor that orchestrates excessive inflammation by simultaneously facilitating viral entry and driving the assembly of the NLRP3 inflammasome, highlighting the Gal3-NLRP3 axis as a promising therapeutic target to mitigate severe influenza-induced lung injury.
2026-07-26 | Synergistic control of viral persistence via wettability and ion release on antiviral coatings.
Antiviral coating design remains largely empirical due to the lack of quantitative principles linking interfacial properties to viral persistence under realistic conditions. Here, we establish a survival time-based evaluation framework that captures the drying dynamics of 2-μL virus-containing microdroplets and enables quantitative assessment of antiviral coating performance using viral survival time (duration of infectivity) and survival time reduction rate. Using this framework, we identify surface virus density, defined as infectious virus per unit distribution area, as a physical determinant governing viral persistence. When surface virus density was matched, viral survival times converged irrespective of inoculum level or droplet geometry. Accordingly, viral survival time decreased with decreasing surface virus density, and hydrophilic surface design alone reduced viral survival time by approximately 70-80%. Furthermore, we demonstrate that the initial release rate of antiviral metal ions constitutes a complementary chemical control parameter under rapid-drying conditions. Antiviral coatings incorporating amorphous vanadate glass particles enabled rapid release of copper or silver ions within the first 1-5 min following droplet deposition. By integrating wettability-mediated viral redistribution with rapid ion release, synergistic suppression of viral persistence was achieved, reducing viral survival time relative to uncoated surfaces by up to 97.6% for influenza virus, 98.2% for feline calicivirus, and 94.9% for highly pathogenic avian influenza virus. These findings demonstrate that viral persistence can be predictively controlled through the combined physical regulation of surface virus density and chemical inactivation by rapidly released antiviral agents. This antiviral coating strategy may contribute to reducing contact transmission risks in healthcare, agricultural, and community environments.
vaccines
2026-09-26 | Elicitation of Potent H5N1- and H7N9-Neutralizing Antibody Responses in Rhesus Macaques by Sequential Heterologous Vaccination with mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins.
Highly pathogenic avian influenza (HPAI) represents an enormous pandemic risk amid the ongoing H5N1 panzootic. HPAI, defined by its high lethality in domestic poultry, includes the influenza A virus (IAV) H5N1 and H7N9 subtypes and has a 40-50% case fatality rate in humans. To facilitate the development of efficacious HPAI vaccination regimens and isolation of HPAI-neutralizing monoclonal antibodies (nmAbs) for prophylactic and therapeutic use, we performed a proof-of-concept pilot study wherein we developed an array of mRNA and adenovirus-vectored vaccines encoding HPAI hemagglutinins (HAs) and then assessed their immunogenicity in IAV-naïve Indian rhesus macaques (RMs). All RMs developed binding IgG recognizing both HPAI HAs. HPAI-nAbs were detected in RMs vaccinated with full-length HAs, but not in RMs vaccinated with HA stems alone. Potent HPAI neutralization activity was observed in two animals with serum ID50 titers of ~1:100,000 against H5N1 and ~1:50,000 against H7N9. Most RMs developed cross-reactive IgG recognizing the HAs of additional IAV subtypes, and HA-specific B cells were readily identifiable in vaccinee PBMCs by flow cytometric analysis. The results of our pilot study suggest that elicitation of potent HPAI-nAb responses is enhanced by vaccination with the HA head domain and that vaccination with the HA stem alone tends to elicit binding non-nAbs. Furthermore, use of our fluorophore-conjugated HA probes to identify HA-specific B cells could enable HPAI-nmAb isolation. Collectively, our findings could facilitate the development of novel vaccines and nmAb therapeutics leveraging the superior neutralization potency of HA head-specific Abs to prevent and treat HPAI infections in humans.
2026-09-26 | Analysis of HA5 Hemagglutinins from Influenza A Viruses for Mass-Charge Patterns to Understand Antigenic Drift Related to Immune Escape.
Influenza A viruses remain a persistent global health threat due to their ability to mutate and evade host immune defences, a process largely driven by changes in hemagglutinin (HA). HA is a glycoprotein present on the surface of influenza virions and plays a critical role in viral entry into host cells by binding to cellular receptors. In this study, 23 HA5 protein sequences from various influenza viral strains collected from wild birds, seagulls, ducks, geese, and chickens, as well as from humans in mainland China during the period from 2023 to 2024, were analyzed for mass-charge patterns by our predictive modelling algorithm to understand the nonlinear trend of viral evolution, particularly regarding their antigenic drift and immune escape potential. Two critical regions in HA5 proteins were identified and analyzed. The first region is a "mutable zone" (the negative gravity centre identified by mass-charge pattern analysis), which frequently accumulates multiple mutations. This leads to antigenic drift and instability, enabling the virus to evade pre-existing herd immunity. Analyzing and monitoring mass-charge changes may help predict the evolutionary trend of the viruses and the emergence of future variants in these regions where the viruses were collected, thereby informing the design and development of vaccines for the viruses analyzed and related strains. The second region is a "stable core" (positive gravity centre), a highly conserved region essential for viral function. Due to its conservation across strains, it may represent a promising target for developing universal vaccines and broad-spectrum antibodies capable of conferring protection against multiple variants simultaneously for the viruses analyzed and related strains. In summary, our analyses, with a predictive modelling algorithm for mass-charge patterns of HA5 protein sequences, provide a novel metric for viral evolution and evaluating the immune evasion potential, and offer a strategic framework for designing vaccines against the viruses analyzed and related strains.
2026-09-13 | Development and evaluation of a recombinant bivalent HVT-vectored vaccine candidate against H9N2 avian influenza virus and fowl adenovirus serotype 4.
H9N2 subtype avian influenza virus (AIV) is one of the most prevalent AIV subtypes in poultry worldwide. Meanwhile, fowl adenovirus serotype 4 (FAdV-4), associated with hepatitis-hydropericardium syndrome (HHS), has been widely distributed in poultry worldwide and has circulated in China since 2015. Notably, co-infections with H9N2 AIV and FAdV-4 are frequently reported in the field, leading to increased mortality and substantial economic losses in the poultry industry. Herpesvirus of turkeys (HVT) has been extensively used as a viral vector for poultry vaccines. In this study, a recombinant bivalent HVT-vectored vaccine candidate (HVT-H9-FAd) co-expressing the hemagglutinin (HA) gene of H9N2 AIV and the Fiber-2 gene of FAdV-4 was constructed and evaluated. The recombinant virus exhibited plaque morphology and growth kinetics comparable to the parental HVT strain and stably expressed HA and Fiber-2 proteins for 20 serial passages. Immunization of specific-pathogen-free (SPF) chickens with HVT-H9-FAd induced robust antibody responses against H9N2 AIV and Fiber-2, with antibody kinetics comparable to those elicited by the corresponding monovalent HVT-H9 and HVT-FAd. Following challenge with the homologous H9N2 AIV strain, HVT-H9-FAd immunized chickens were completely protected, with no detectable viral shedding. Following challenge with the homologous FAdV-4 strain, complete protection was observed, as evidenced by the absence of mortality, viral replication, and pathological lesions in immunized chickens. Collectively, these findings demonstrate that the recombinant HVT-H9-FAd is a promising bivalent vaccine candidate for controlling H9N2 AIV and FAdV-4 in poultry and provides an effective strategy for preventing co-circulating pathogens in chicken flocks.
2026-09-09 | Highly efficient intranasal H5N1 vaccine based on a safe vesicular stomatitis virus (VSV) vector.
Recombinant vesicular stomatitis virus (rVSV) is an increasingly popular vaccine vector, but it still faces challenges such as difficulties in construction, low in vitro amplification titers, safety concerns, and uncertain mucosal immune effects. Therefore, there is an urgent need to construct new VSV vectors for next-generation vaccines with high immunogenicity and excellent safety. In this study, we independently constructed a high-expression 6-9G recombinant replication-competent VSV vector. Based on the 6-9G vector, site-directed mutations were introduced into the M gene, including deletion of the 51st amino acid (Δ51), Δ51 + V221F, and Δ51 + S226R, to generate vectors designated as 6-9G-Δ51, 6-9G-Δ51 + V221F, and 6-9G-Δ51 + S226R. Through in vitro replication kinetics and in vivo immunogenicity studies, we identified 6-9G-Δ51 + S226R vector with a favorable safety profile and strong immunogenicity. The highly pathogenic avian influenza virus H5 subtype clade 2.3.4.4b poses a global pandemic threat, urgently necessitating new strategies for its prevention and control. Based on the 6-9G-Δ51 + S226R vector, we constructed the 6-9ΔGΔ51+S226R-H5N1 influenza virus vectored vaccine by replacing the VSV-G gene with the HA and NA genes. This candidate demonstrated further improved safety while eliciting robust and durable humoral as well as mucosal immune responses after two doses, providing 100% protection in mice against lethal viral challenge. The successfully developed novel 6-9ΔGΔ51+S226R-H5N1 vaccine candidate not only exhibits excellent safety and immunogenicity but also represents a powerful potential tool for the effective prevention and control of highly pathogenic avian influenza.
2026-09-04 | Safety, humoral and cellular immune responses to a pre-pandemic adjuvanted influenza A (H5N8) vaccine.
Highly pathogenic avian influenza (HPAI) A(H5) viruses can be transmitted from infected birds to various mammalian species, including humans. Avian influenza viruses (AIVs), members of the Orthomyxoviridae family, possess segmented RNA genomes prone to reassortment, favoring the emergence of novel genetic traits that may alter transmissibility, pathogenicity, and antigenicity. Although no sustained human-to-human transmission has been reported, the potential adaptation of these viruses poses a significant pandemic threat. This study aimed to evaluate the non-clinical safety, toxicity, and humoral immune responses induced by an adjuvanted H5 influenza vaccine in rats and rabbits, to support future clinical safety trials in humans. Male and female Wistar rats and New Zealand rabbits were observed for 14, 28, and 90 days after receiving two intramuscular doses of the H5N8 vaccine (15 μg HA/dose) formulated with the IB160 oil-in-water emulsion adjuvant. No systemic comorbidities, central nervous system alterations, or relevant clinical signs were observed. Hematological parameters remained within normal ranges, with total and differential leukocyte counts showing only minor fluctuations (<1% of total leukocytes). Mild biochemical variations in urea and hepatic transaminase levels were not correlated with histopathological alterations. The vaccine elicited a robust humoral response soon after immunization, with all groups reaching protective HAI-antibody titers. Although antibody levels declined over time, particularly in males, they remained significantly above baseline, indicating durable immunological memory. Furthermore, the vaccine induced a specific cellular immune response, confirmed by IL-2 and TNF production by antigen-specific T lymphocytes in splenic cell cultures after the booster dose. In conclusion, the H5N8 vaccine with the IB160 adjuvant was well tolerated locally and systemically, without compromising vital organ function. The safety and immunogenicity findings are consistent with expectations for adjuvanted influenza vaccines, demonstrating strong and durable humoral and cellular immune responses.
proteins
2026-09-22 | Interaction between DEAD-box RNA helicase 10 and influenza PB1 polymerase selectively regulates influenza A virus replication.
Identifying the host factors that mediate avian influenza virus adaptation in mammals is important for monitoring zoonotic potential. Although viral polymerase adaptations are known to influence cross-species transmission, the engagement of specific host factors with divergent viral polymerases remains to be explored. We examined human DEAD-box RNA helicases (DDXs) as potential regulators of influenza polymerase activity. A screen of 16 DDXs identified DDX10 as a factor that selectively enhanced the polymerase activity and replication of human-adapted H1N1 viruses, including the 2009 pandemic strain, but not avian-origin H9N2 viruses. This differential activity was associated with DDX10 showing stronger interaction with human-origin PB1 (Cal04/H1N1) than with avian-origin PB1 (BJ16/H9N2). Strain specificity was mediated by two residues (336 and 364) within the PB1 catalytic domain: introducing H1N1-type residues (I336 and I364) into H9N2-PB1 conferred DDX10 responsiveness, while reciprocal mutations in H1N1-PB1 abolished it. This work defines DDX10 as a potential host factor that differentially supports influenza polymerase activity, revealing a specific molecular interface that contributes to the replication efficiency of distinct viral subtypes in human cells and providing insight into host-adaptive mechanisms. This study identifies DDX10 as a strain-specific host factor that differentially regulates influenza A virus replication. By demonstrating that DDX10 selectively enhances human-adapted H1N1 viruses over avian-origin H9N2 viruses through direct interaction with the viral PB1 protein, and by mapping two critical residues (positions 336 and 364) in PB1 that govern this selectivity, our work provides a mechanistic framework for understanding how a single host factor can modulate viral fitness and host adaptation. These findings have important implications for predicting cross-species transmission potential and may guide the development of host-targeted antiviral strategies.
2026-08-21 | Computational insights into the inhibitory potential of cyclotides Psyle B and Psyle C against key surface proteins of avian influenza H5N1.
Avian influenza viruses (AIVs) are RNA viruses endemic to wild birds, with highly pathogenic strains such as H5N1 causing major outbreaks. Hemagglutinin (HA) and neuraminidase (NA) proteins are key mediators of viral entry and spread. Cyclotides, plant-derived peptides with stable structures and potent bioactivity, have emerged as novel antiviral candidates. This study explored cyclotide-based drug design against H5N1 using computational approaches. HA and NA protein sequences were retrieved from NCBI and their physicochemical properties analyzed using ProtParam. Cyclotides from CyBase were modeled and refined in PyMOL, followed by molecular docking via ClusPro. Binding energies were further assessed with molecular mechanics generalized born surface area, while toxicity was predicted using ToxinPred. Molecular dynamics simulations supported the stability analyses. Results revealed that Psyle B and Psyle C exhibited strong interactions with HA and NA. Psyle B achieved a docking score of -1001.3 kcal/mol, and Psyle C -1031.6 kcal/mol, both predicted as non-toxic. These findings highlight Psyle B and Psyle C as promising antiviral leads. Nonetheless, in vitro and in vivo validation remains essential to confirm their therapeutic potential.
2026-08-13 | Identification and characterization of PB2 mutations associated with mammalian adaptation of highly pathogenic H5N1 avian influenza viruses.
The highly pathogenic avian influenza virus (HPAIV) subtype H5N1 has been continuously circulating among wild bird populations and domestic poultry. It's ongoing circulation has led to outbreaks in poultry and U.S. dairy cattle populations, as well as sporadic severe infections in individuals engaged in poultry and dairy farming. These occurrences have raised concerns about the potential evolution of this virus into a pandemic strain. To elucidate the molecular determinants facilitating H5N1 cross-species adaptation and to evaluate its implications for public health, we conducted serials of sequence analysis and specific-site mutations on the viral polymerase subunit PB2 to determine its effect on polymerase activity and viral infectivity. The results showed that three mutations in the PB2 protein (E362G, D441N and M631L) were presented cooperative effects associated with enhanced viral replication in mammalian cells. Compared to the original isolated strain of the 2.3.4.4b clade, A/chicken/NL/FAV-0033/2021, these three mutations were predominantly identified in isolates obtained from cattle and other mammalian hosts between 2021 and 2024. The M631L mutation, identified as the primary determinant of increased polymerase activity in mammalian cells, significantly enhanced the binding affinity of PB2 to ANP32A. The mutation E362G and D441N did not increased polymerase activity and viral replication significantly but enhanced binding affinity of PB2 to ANP32A. The combined mutations with E362G, D441N and M631L resulted in a significantly increased polymerase activity and viral replication in H5N1 virus, and significantly elevated viral loads and aggravated pulmonary pathology in lungs of mice with H5N1 infection. These findings indicate that the PB2-M631L mutation constitutes a crucial molecular marker for the adaptation of H5N1 to mammalian hosts, whereas the E362G and D441N mutations likely function as supportive modulatory factors that optimize this host-adaptation process.
2026-08-11 | Identification and functional characterization of a novel antiviral chicken interferon-υ.
Interferons are critical mediators of antiviral immunity in vertebrates. While type IV interferon (IFN-υ) has been identified in fish and amphibians, its existence and function in chickens remained unknown. Through systematic genomic screening, we identified and cloned a novel chicken interferon gene, designated ChIFN-υ. Phylogenetic analysis placed ChIFN-υ within a distinct clade alongside zebrafish and clawed frog IFN-υ, confirming its identity as a type IV interferon, with minimal homology to classical type I, II, or III IFNs. Expression profiling revealed constitutive ChIFN-υ expression in mucosal and immune tissues of healthy chickens, exhibiting a distinct developmental shift: highest in trachea and small intestine in 1-day-old chicks, shifting to spleen and lung in 4-week-old chickens. ChIFN-υ expression was strongly upregulated following H9N2 AIV infection. Functionally, recombinant ChIFN-υ protein activated the interferon-stimulated response element (ISRE) and Mx promoter in a dose-dependent manner and significantly inhibited the replication of both vesicular stomatitis virus (VSV) and H9N2 AIV in DF-1 cells. In vivo, early treatment with exogenous ChIFN-υ significantly reduced pulmonary and tracheal viral loads and decreased oropharyngeal and cloacal virus shedding in H9N2-infected chickens. In conclusion, this study identifies and functionally characterizes the type IV interferon in chickens, elucidating the evolutionary status, regulated expression, and antiviral efficacy of ChIFN-υ. These findings highlight its potential as a candidate for developing interferon-based therapies against avian viral diseases.
2026-06-26 | Avian Foxp3 acts as a switch for IL-10 by directly binding the T3G motif: revealing a novel epigenetic modulation paradigm.
Foxp3 is the master transcription factor for regulatory T (Treg) cell differentiation and function, essential for immune homeostasis and tolerance. While its role is well-characterized in mammals, its functional mechanisms in avian species remain poorly understood. We conducted comparative genomic and functional analyses of chicken Foxp3 (chFoxp3). DNA-binding specificity was determined using motif analysis and genome-wide scanning. An H9N2 avian influenza challenge model was used to assess Foxp3 expression dynamics and CD4⁺CD25⁺ T cell frequency in vivo. The transcriptional regulation of IL-10 by chFoxp3 was investigated through promoter binding and transactivation assays, with key domains mapped via mutagenesis. Avian Foxp3 has evolved independently from its mammalian ortholog. Unlike human Foxp3, which binds the FKHM motif, chFoxp3 specifically recognizes a T3G microsatellite motif. Genome-wide scanning identified potential targets enriched in the FoxO signaling pathway, including IL-10. In an H9N2 infection model, Foxp3 expression and CD4⁺CD25⁺ T cell frequency exhibited biphasic dynamics. Mechanistically, chFoxp3, but not human FoxP3, directly binds the T3G motif in the IL-10 promoter to activate transcription. This transactivation function critically depends on the HNT linker within its Fork-head domain. Our study reveals a novel mode of transcriptional regulation by chFoxp3 via T3G motif recognition, underscoring its functional diversification during evolution. These findings provide a foundation for understanding immune regulation in birds under both physiological and pathological conditions, such as avian influenza infection.
other
2026-09-07 | Transcriptome screening identifies circRNA-INSR as a novel host factor associated with avian influenza virus replication.
Circular RNAs (circRNAs) represent a class of covalently closed non-coding RNA molecules that exert vital regulatory effects on host-pathogen interplay. The H9N2 subtype of avian influenza virus (AIV) is a widespread pathogen on a global scale, inflicting considerable economic damage to the poultry sector and harboring potential risks of cross-species transmission to humans. Despite growing evidence suggesting that non-coding RNAs can modulate the replication of influenza viruses, the expression patterns and functions of avian-derived circRNAs during H9N2 AIV infection have been largely unclear. Here, we conducted a systematic investigation into the expression dynamics of circRNAs in DF1 cells infected with H9N2 AIV by high-throughput RNA sequencing technology. A total of 139 differentially expressed circRNAs were identified, with 58 exhibiting upregulation and 81 showing downregulation relative to non-infected control cells. Of note, a circRNA originating from exon 2 of the insulin receptor (INSR) gene displayed consistent upregulation during viral infection. Functional assays verified its contributing role in the replication of H9N2 AIV. Specifically, siRNA-mediated knockdown of circ-INSR significantly suppressed H9N2 AIV replication. This study is the first to identify circ-INSR as a host factor contributing to influenza virus replication. Our results provide a basis for developing circRNA-based strategies against H9N2 avian influenza virus.
2026-09-03 | A Rationally Designed Split Lettuce Aptamer Based on Large-Scale Mutational Analysis.
Split-aptamer biosensors offer exceptionally low background by assembling only in the presence of a target analyte; however, their performance is frequently limited by the lack of robust design rules for selecting effective split sites. Existing approaches largely rely on heuristic, structure-based assumptions that are poorly validated and often yield suboptimal signal. Herein, we introduce a systematic, data-driven strategy for identifying high-performance split sites within fluorogenic DNA aptamers. Using our massively parallel aptamer performance analyzer platform, we performed comprehensive single- and double-mutant analysis of the DFAME-binding region of the fluorogenic DNA aptamer Lettuce, informed by its three-dimensional structure. Dimensionality reduction and clustering of the resulting sequence-function landscape revealed mutation-tolerant elements within the binding domain that are suitable for splitting while preserving fluorophore activation. Sensors constructed using these nonintuitive split sites, which are unconventional by standard design principles, exhibited a nearly four-fold improvement in the fluorescence signal-to-background ratio for SARS-CoV-2 RNA detection compared to a prior split-Lettuce design. The same split architecture also enabled robust detection of high-pathogenicity H5Nx avian influenza RNA. These results demonstrate that large-scale, data-driven interrogation of aptamer sequence-function relationships can identify nonintuitive split sites and provide a proof-of-concept framework for developing measurement-based design principles for split-aptamer biosensors.
2026-07-30 | Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice.
Self-amplifying mRNA (samRNA) vaccines can induce potent immune responses at lower doses than conventional non-replicating mRNA vaccines; however, large RNA size and manufacturing considerations associated with 5' capping remain important challenges. Here, we developed a capless samRNA (CLsamRNA) vaccine platform derived from a Coxsackievirus B5 replicon that uses internal ribosome entry site-mediated cap-independent translation. Systematic optimization of key genetic elements enhanced antigen expression from the CLsamRNA backbone. Using reporter RNAs, LNP-formulated CLsamRNA showed rapid early expression and RNA amplification, with expression kinetics distinct from VEEV-based saRNA and nucleoside-modified mRNA comparators. When encoding the hemagglutinin antigen of highly pathogenic avian influenza clade 2.3.4.4 H5 viruses, CLsamRNA induced potent immune responses after LNP formulation. In mouse models, CLsamRNA induced potent neutralizing antibody responses, cross-reactive activity against clade 2.3.4.4b H5N1 virus, Th1-skewed humoral immunity, and strong antigen-specific cellular immune responses. CLsamRNA also elicited platform-specific early inflammatory and lymph node immune gene signatures associated with antigen presentation, costimulation, and cellular immune priming. Notably, a minimal 0.01-μg dose of CLsamRNA conferred complete protection against lethal H5N8 influenza virus challenge in BALB/c mice. These findings support CLsamRNA as a distinct cap-independent RNA vaccine platform with dose-sparing protective efficacy against highly pathogenic avian influenza H5 viruses.
2026-07-17 | Characterization of bovine-derived H5N1 viruses expressing fluorescent and luminescent reporter proteins.
Highly pathogenic avian influenza H5N1 clade 2.3.4.4b viruses present a broad host range, with recent spillover and sustained transmission in dairy cattle reported in the USA. Replication-competent reporter viruses are critical tools that enable real-time monitoring of virus replication, facilitating high-throughput screens. In this study, we engineered three recombinant H5N1 clade 2.3.4.4b reporter viruses expressing nanoluciferase (NLuc) and two fluorescent reporter proteins, miniGFP2 and UnaG within the open reading frame of the nonstructural gene of the bovine A/Cattle/Texas/063224-24-1/2024 (TX2/24) virus. All reporter viruses replicated efficiently in vitro, presenting replication kinetics comparable to the parental rTX2/24 virus, but exhibited smaller plaque sizes, suggesting reduced cell-to-cell spread. In vivo infection studies in mice showed comparable pathogenicity among all four viruses, although rTX2/24-miniGFP2 and rTX2/24-UnaG exhibited decreased virus shedding relative to rTX2/24 and rTX2/24-NLuc. Virus titrations and in situ localization of virus replication sites demonstrated robust replication in respiratory tissues, with slightly attenuated systemic dissemination of all three reporter viruses. Fluorescent virus neutralization assays using miniGFP2 and UnaG reporter viruses accurately quantified neutralizing antibody titres in sera from naturally infected dairy cattle, consistent with wild-type virus assays. Additionally, the utility of the NLuc reporter virus for antiviral screening was validated against oseltamivir in vitro. Collectively, these results establish the H5N1 TX2/24-based reporter viruses as versatile and biologically relevant tools for investigating H5N1 pathogenesis and for use in serological and antiviral drug screens.
2026-07-09 | Characterization of oseltamivir-resistant A(H5N1) clade 2.3.4.4b, genotype D1.1 variants identified in poultry farms of British Columbia, Canada.
Highly pathogenic avian influenza A(H5N1) viruses of clade 2.3.4.4b, genotype D1.1, are responsible for widespread outbreaks in poultry and continue to cause sporadic, sometimes severe, human infections. Herein, we characterized a wild-type (WT) influenza A(H5N1) D1.1 isolate (BC-H5N1-WT) and its H275Y neuraminidase (NA) variant (BC-H5N1-H275Y), both of which emerged on farms in British Columbia, Canada, during the fall 2024 outbreak. In vitro analysis assessed replication kinetics in MDCK cells, with supernatants collected at different days post-infection (p.i.) and titrated by TCID50 and qRT-PCR. Neuraminidase inhibitor (NAI) susceptibility was determined by NA inhibition assays, whereas susceptibility to baloxavir acid (BXA) was evaluated by plaque reduction assay. In vivo virulence was evaluated in BALB/c mice infected with serial 10-fold dilutions of each virus to monitor weight loss and mortality. Viral titers in lungs, brain, nose, kidney, spleen, and heart were quantified at day 4 p.i. The BC-H5N1-WT virus was susceptible to the four antivirals tested, whereas BC-H5N1-H275Y displayed resistance to oseltamivir and peramivir but remained susceptible to zanamivir and BXA. The BC-H5N1-WT exhibited significantly higher viral replication titers than BC-H5N1-H275Y at all tested time points and showed larger plaque sizes. In mice, BC-H5N1-WT was more virulent with LD50 values of 1.78 × 103 PFUs compared to 8.71 × 104 PFUs for BC-H5N1-H275Y, and produced higher viral titers in lungs and other organs. Despite the reduced fitness of the resistant H5N1 D1.1 variant, its emergence in the absence of viral selection pressure underscores the need for continued surveillance.
antibodies
2026-09-30 | Highly Pathogenic Avian Influenza Virus Subtype 5 in Cetaceans, Brazil.
We identified highly pathogenic avian influenza virus subtype H5 in stranded dolphins along the coastline of Brazil during 2023-2025. Infected animals included species classified as vulnerable or endangered. Our results highlight the need for ongoing surveillance of cetaceans susceptible to viral infections, which pose an additional threat to threatened species.
2026-09-18 | H5N1 clade 2.3.2.1e lineage transition in Lao PDR during 2023-2024 associated with regional spread and human infection risk-associated receptor-binding features.
Highly pathogenic avian influenza (HPAI) H5N1 viruses clade 2.3.2.1e has re-emerged in the Indochinese Peninsula, raising concerns about regional spread and zoonotic risk. We characterized eight H5N1 viruses isolated from 32 environmental and poultry-derived samples collected in Lao People's Democratic Republic (Lao PDR) live bird markets during 2023-2024. Whole-genome and phylogenetic analyses showed that all isolates belonged to clade 2.3.2.1e and were distinct from the previously dominant Lao clade 2.3.2.1c, indicating lineage transition in poultry-associated viruses. The Lao isolates were distributed across regional sublineages rather than forming a single local cluster, suggesting repeated introductions and cross-border genetic connectivity. Segment-level nucleotide identities ranged from 97.2 to 99.9%, revealing a complex mosaic genotype constellation. All isolates retained the avian-associated glutamic acid residue at position 627 of polymerase basic protein 2 (PB2-627E) and the aspartic acid residue at position 701 of polymerase basic protein 2 (PB2-701D). Hemagglutinin (HA) analysis showed a conserved polybasic cleavage motif, PQRERRRKRGLF, and conserved HA1-123S, HA1-154N, HA1-263T, and HA2-497L, whereas isolate-level variation was observed at HA1-94, HA1-188, and HA1-223. Structural modeling and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) analysis of a representative isolate further highlighted receptor binding site (RBS) associated HA features. Importantly, RBS-associated HA variation was detected despite the absence of lysine residue at position 627 of polymerase basic protein 2 (PB2-627 K), suggesting that early molecular changes relevant to mammalian or human adaptation may arise before acquisition of canonical mammalian-adaptive polymerase mutations. These findings support sustained cross-border genomic surveillance and receptor-binding-focused characterization of H5N1 viruses circulating in Lao live bird markets.
2026-09-16 | Experimental Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Alpacas, 2026.
Highly pathogenic avian influenza (HPAI) A(H5N1) clade 2.3.4.4b virus continues to spread globally and sporadically transmits from avian reservoirs to mammalian hosts. In May 2024, H5N1 infections in young goats and alpacas in the United States were reported. Nevertheless, the overall susceptibility of camelids to clade 2.3.4.4b virus remains unclear. We conducted a controlled experimental infection study in 6 alpacas, assessing clinical signs, viral shedding, tissue distribution, and serologic responses after intranasal inoculation with HPAI H5N1 genotype B3.13 virus. Observed illness was generally mild; body temperature increased slightly and food intake reduced for up to 3 days postinfection. We detected viral RNA in nasal swab samples and confirmed infectious HPAI H5N1 virus. Immunohistochemistry and RNA in situ hybridization detected virus only in the nasopharyngeal tonsil and nasal conchae at 4 days postinfection. Our findings suggest alpacas are susceptible to productive H5N1 infection, highlighting implications for livestock surveillance and biosecurity in regions with ongoing circulation.
2026-09-15 | Enhanced induction of inflammatory cytokines in human lung cells infected with highly pathogenic recent H5N1/2024 avian influenza virus.
Highly pathogenic (HP) H5N1 avian influenza viruses are zoonotic pathogens and are endemic in wild birds and poultry around the world. Pro-inflammatory cytokines are supposed to contribute to the severe clinical symptoms in infected animals and humans. In this study, we determined the infectivity and cytokine induction in primary human lung cells infected with HP H5N1 avian influenza viruses and seasonal H3N2 influenza viruses. MDCK cells were used to measure viral titers in the supernatants of infected human lung cells by log10TCID50/ml. Quantitative real-time PCR was used to detect the induction of cytokine genes using mRNA from the infected primary human lung cells. HP H5N1 avian influenza viruses induced higher viral titers than seasonal H3N2 influenza viruses in supernatants of primary human lung cells. In addition, HP H5N1avian influenza viruses induced the genes of pro-inflammatory cytokines such as IL-23, IL-1α, IL-1β, IL-6, and IL-8 at significantly higher levels than seasonal H3N2 influenza viruses in primary human lung cells. Our data suggest that the high viral replication and the high induction of pro-inflammatory cytokines in the human lung cells infected with HP H5N1 avian influenza viruses may enhance pathogenicity in the infected humans as compared to seasonal H3N2 influenza viruses.
2026-09-14 | Genomic detection of highly pathogenic avian influenza H5N1 in Antarctic seabirds reveals connectivity with South American viral lineages.
Emerging avian viruses increasingly threaten Antarctic wildlife, raising concerns about ecosystem health and biodiversity. In this study, we conducted a comprehensive investigation of avian influenza virus (influenza A virus, IAV) in both resident and migratory birds inhabiting the South Shetland Islands, Antarctica. During the 2024-2025 austral summer, 278 samples were collected and screened using real-time RT-PCR targeting the IAV M gene. IAV RNA was detected in 30 samples, and eight of these were found to be positive for H5. Complete genome sequencing was performed on samples from a gentoo penguin (Pygoscelis papua) and a southern giant petrel (Macronectes giganteus), revealing the presence of highly pathogenic avian influenza virus H5N1, clade 2.3.4.4b. Phylogenetic analysis demonstrated that these viral genomes closely cluster with contemporary South American strains, indicating a direct connectivity between Antarctic seabirds and the broader H5N1 transmission network. Our findings highlight the heightened vulnerability of Antarctic ecosystems to emerging infectious diseases and emphasize the critical need for sustained genomic surveillance. These efforts are essential to monitor wildlife health, inform conservation strategies, and implement effective biosecurity measures to safeguard Antarctic biodiversity.
small molecules
2026-09-30 | Baloxavir-Based Combination Therapy for Protection against Influenza A(H5N1) Clade 2.3.4.4b Virus Infection in Mice.
Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus continues to cause animal outbreaks and sporadic zoonotic infections. In a mouse model of lethal influenza disease, we compared oseltamivir, baloxavir, and molnupiravir monotherapies with 2-drug combinations. Baloxavir-based combinations improved survival, reduced lung viral loads, and prevented extrapulmonary dissemination, supporting H5N1 preparedness strategies.
2026-09-16 | In silico evaluation of selected plant-based compounds as potent dual target inhibitors against highly pathogenic avian influenza H5N1 virus.
1. Influenza viruses remain a serious global health issue due to their high morbidity and mortality rates. Among them, avian influenza H5N1 virus is highly pathogenic, causing up to 100% mortality in poultry. As the avian influenza H5N1 virus continues to mutate across different regions, understanding multiple viral proteins, particularly the mutated haemagglutinin (HA) and neuraminidase (NA), is crucial for effective control.2. In this study, dual-target inhibitors capable of neutralising both HA and NA were developed, and a comprehensive in silico analysis was performed on different variants collected over the past decade. Structural modelling revealed conserved domains in NA (A0A1I9QM14, China) and HA (A0A0A0V4U2, Bali), which were selected for ligand docking.3. Twenty active compounds, traditionally used as natural feed additives in broiler chicken diets, were screened using protein-ligand docking, ADME profiling, and molecular dynamics (MD) simulations. Quercetin and luteolin emerged as promising dual-target inhibitors, showing high binding affinity, drug-likeness, and favourable toxicity profiles. The binding free energy (ΔG = -8 ± 0.2 kcal/mol) from docking studies confirmed their inhibitory potential against avian influenza H5N1 virus HA and NA.4. The results demonstrated that virtual screening of natural compounds can effectively identify those effective against influenza virus surface proteins. This integrative computational-experimental strategy supported the development of novel plant-derived antiviral agents with potential applications for disease control.
2026-08-25 | Hypoxia-inducible factor 1-alpha inhibition mitigates inflammatory responses induced by H9N2 avian influenza virus.
H9N2 avian influenza virus (AIV) poses significant threats to poultry and public health, with the potential to contribute to the emergence of more virulent influenza strains. Hypoxia-inducible factor 1-alpha (HIF-1α) plays a crucial role in viral pathogenesis, immune regulation, and inflammation, making it a promising target for therapeutic intervention. Here, we explored the involvement of HIF-1α in H9N2 AIV pathogenesis and associated inflammatory responses. Our data revealed that HIF-1α exacerbates inflammation induced by H9N2 AIV infection through its regulation of mitochondrial fitness. Additionally, we investigated Sotetsuflavone (Seo), a naturally derived flavonoid, for its potential to modulate inflammatory responses following H9N2 infection. Molecular docking coupled with surface plasmon resonance assays indicated that Seo exhibits robust binding affinity to HIF-1α, implying a direct inhibitory mechanism. Subsequent in vitro studies demonstrated that Seo greatly reduced the production of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, through suppressing the HIF-1α signaling pathway in HD11 cells infected with H9N2 AIV. Correspondingly, in vivo experiments established that Seo administration significantly ameliorated pulmonary inflammation in H9N2-infected mice, while also enhancing alveolar epithelial repair, as evidenced by increased expression of type II alveolar epithelial cell markers Abca3 and Sftpb. Collectively, these findings identify Seo as a potent inhibitor of HIF-1α, highlighting its therapeutic potential in mitigating inflammation and lung damage associated with influenza virus infection.IMPORTANCEH9N2 avian influenza virus triggers inflammatory lung injury via hypoxia-inducible factor-1 alpha (HIF-1α)-mediated dysregulation of mitochondrial function. The natural flavonoid Sotetsuflavone (Seo) directly binds and inhibits HIF-1α, as confirmed by molecular docking and surface plasmon resonance assays. In H9N2-infected HD11 cells, Seo suppresses HIF-1α signaling, reducing IL-1β, IL-6, and TNF-α production. In vivo, Seo treatment attenuates pulmonary inflammation and enhances alveolar epithelial repair in mice, upregulating type II pneumocyte markers (Abca3 and Sftpb). These findings identify Seo as a promising HIF-1α-targeted therapeutic for influenza-associated immunopathology.
2026-08-22 | Galectin-3 exacerbates influenza a virus pathogenesis via dual mechanisms: Promoting hemagglutinin-dependent entry and driving nlrp3 inflammasome activation.
Influenza A viruses (IAVs), particularly highly pathogenic avian influenza (HPAI) strains like H5N1 and H7N9, cause severe pneumonia and acute respiratory distress syndrome (ARDS) driven by dysregulated cytokine storms. A key mediator of this immunopathology is the excessive activation of the NLRP3 inflammasome, which governs the maturation of IL-1β. Galectin-3 (Gal3), a β-galactoside-binding lectin, is upregulated during infection; however, its specific regulatory role in coordinating NLRP3 inflammasome activation across distinct viral hemagglutinin (HA) subtypes remains to be elucidated. In this study, we demonstrate that Gal3 functions as a critical amplifier of influenza pathogenesis through a distinct dual-stage mechanism. Results from viral binding and internalization assays indicate that extracellular Gal3 promotes viral entry by interacting with viral HA, an effect that is strictly strain-dependent (H5N1 > H1N1 > H7N9). This enhanced entry consequently amplifies the initial signal for inflammasome activation. Intracellularly, Gal3 regulates the NLRP3 cascade by sustaining NF-κB activation (priming) to upregulate NLRP3 and pro-IL-1β transcription and acting as a facilitator to strengthen the NLRP3-ASC-pro-caspase-1 interaction, promoting ASC oligomerization (activation). Consistently, in vivo studies demonstrate that Gal3-deficient mice exhibit significantly improved survival, reduced weight loss, and attenuated pulmonary inflammation and IL-1β release following infection, with the most pronounced protective effects observed against H5N1. Collectively, these findings identify Gal3 as a potent host factor that orchestrates excessive inflammation by simultaneously facilitating viral entry and driving the assembly of the NLRP3 inflammasome, highlighting the Gal3-NLRP3 axis as a promising therapeutic target to mitigate severe influenza-induced lung injury.
2026-07-26 | Synergistic control of viral persistence via wettability and ion release on antiviral coatings.
Antiviral coating design remains largely empirical due to the lack of quantitative principles linking interfacial properties to viral persistence under realistic conditions. Here, we establish a survival time-based evaluation framework that captures the drying dynamics of 2-μL virus-containing microdroplets and enables quantitative assessment of antiviral coating performance using viral survival time (duration of infectivity) and survival time reduction rate. Using this framework, we identify surface virus density, defined as infectious virus per unit distribution area, as a physical determinant governing viral persistence. When surface virus density was matched, viral survival times converged irrespective of inoculum level or droplet geometry. Accordingly, viral survival time decreased with decreasing surface virus density, and hydrophilic surface design alone reduced viral survival time by approximately 70-80%. Furthermore, we demonstrate that the initial release rate of antiviral metal ions constitutes a complementary chemical control parameter under rapid-drying conditions. Antiviral coatings incorporating amorphous vanadate glass particles enabled rapid release of copper or silver ions within the first 1-5 min following droplet deposition. By integrating wettability-mediated viral redistribution with rapid ion release, synergistic suppression of viral persistence was achieved, reducing viral survival time relative to uncoated surfaces by up to 97.6% for influenza virus, 98.2% for feline calicivirus, and 94.9% for highly pathogenic avian influenza virus. These findings demonstrate that viral persistence can be predictively controlled through the combined physical regulation of surface virus density and chemical inactivation by rapidly released antiviral agents. This antiviral coating strategy may contribute to reducing contact transmission risks in healthcare, agricultural, and community environments.
vaccines
2026-09-26 | Elicitation of Potent H5N1- and H7N9-Neutralizing Antibody Responses in Rhesus Macaques by Sequential Heterologous Vaccination with mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins.
Highly pathogenic avian influenza (HPAI) represents an enormous pandemic risk amid the ongoing H5N1 panzootic. HPAI, defined by its high lethality in domestic poultry, includes the influenza A virus (IAV) H5N1 and H7N9 subtypes and has a 40-50% case fatality rate in humans. To facilitate the development of efficacious HPAI vaccination regimens and isolation of HPAI-neutralizing monoclonal antibodies (nmAbs) for prophylactic and therapeutic use, we performed a proof-of-concept pilot study wherein we developed an array of mRNA and adenovirus-vectored vaccines encoding HPAI hemagglutinins (HAs) and then assessed their immunogenicity in IAV-naïve Indian rhesus macaques (RMs). All RMs developed binding IgG recognizing both HPAI HAs. HPAI-nAbs were detected in RMs vaccinated with full-length HAs, but not in RMs vaccinated with HA stems alone. Potent HPAI neutralization activity was observed in two animals with serum ID50 titers of ~1:100,000 against H5N1 and ~1:50,000 against H7N9. Most RMs developed cross-reactive IgG recognizing the HAs of additional IAV subtypes, and HA-specific B cells were readily identifiable in vaccinee PBMCs by flow cytometric analysis. The results of our pilot study suggest that elicitation of potent HPAI-nAb responses is enhanced by vaccination with the HA head domain and that vaccination with the HA stem alone tends to elicit binding non-nAbs. Furthermore, use of our fluorophore-conjugated HA probes to identify HA-specific B cells could enable HPAI-nmAb isolation. Collectively, our findings could facilitate the development of novel vaccines and nmAb therapeutics leveraging the superior neutralization potency of HA head-specific Abs to prevent and treat HPAI infections in humans.
2026-09-26 | Analysis of HA5 Hemagglutinins from Influenza A Viruses for Mass-Charge Patterns to Understand Antigenic Drift Related to Immune Escape.
Influenza A viruses remain a persistent global health threat due to their ability to mutate and evade host immune defences, a process largely driven by changes in hemagglutinin (HA). HA is a glycoprotein present on the surface of influenza virions and plays a critical role in viral entry into host cells by binding to cellular receptors. In this study, 23 HA5 protein sequences from various influenza viral strains collected from wild birds, seagulls, ducks, geese, and chickens, as well as from humans in mainland China during the period from 2023 to 2024, were analyzed for mass-charge patterns by our predictive modelling algorithm to understand the nonlinear trend of viral evolution, particularly regarding their antigenic drift and immune escape potential. Two critical regions in HA5 proteins were identified and analyzed. The first region is a "mutable zone" (the negative gravity centre identified by mass-charge pattern analysis), which frequently accumulates multiple mutations. This leads to antigenic drift and instability, enabling the virus to evade pre-existing herd immunity. Analyzing and monitoring mass-charge changes may help predict the evolutionary trend of the viruses and the emergence of future variants in these regions where the viruses were collected, thereby informing the design and development of vaccines for the viruses analyzed and related strains. The second region is a "stable core" (positive gravity centre), a highly conserved region essential for viral function. Due to its conservation across strains, it may represent a promising target for developing universal vaccines and broad-spectrum antibodies capable of conferring protection against multiple variants simultaneously for the viruses analyzed and related strains. In summary, our analyses, with a predictive modelling algorithm for mass-charge patterns of HA5 protein sequences, provide a novel metric for viral evolution and evaluating the immune evasion potential, and offer a strategic framework for designing vaccines against the viruses analyzed and related strains.
2026-09-13 | Development and evaluation of a recombinant bivalent HVT-vectored vaccine candidate against H9N2 avian influenza virus and fowl adenovirus serotype 4.
H9N2 subtype avian influenza virus (AIV) is one of the most prevalent AIV subtypes in poultry worldwide. Meanwhile, fowl adenovirus serotype 4 (FAdV-4), associated with hepatitis-hydropericardium syndrome (HHS), has been widely distributed in poultry worldwide and has circulated in China since 2015. Notably, co-infections with H9N2 AIV and FAdV-4 are frequently reported in the field, leading to increased mortality and substantial economic losses in the poultry industry. Herpesvirus of turkeys (HVT) has been extensively used as a viral vector for poultry vaccines. In this study, a recombinant bivalent HVT-vectored vaccine candidate (HVT-H9-FAd) co-expressing the hemagglutinin (HA) gene of H9N2 AIV and the Fiber-2 gene of FAdV-4 was constructed and evaluated. The recombinant virus exhibited plaque morphology and growth kinetics comparable to the parental HVT strain and stably expressed HA and Fiber-2 proteins for 20 serial passages. Immunization of specific-pathogen-free (SPF) chickens with HVT-H9-FAd induced robust antibody responses against H9N2 AIV and Fiber-2, with antibody kinetics comparable to those elicited by the corresponding monovalent HVT-H9 and HVT-FAd. Following challenge with the homologous H9N2 AIV strain, HVT-H9-FAd immunized chickens were completely protected, with no detectable viral shedding. Following challenge with the homologous FAdV-4 strain, complete protection was observed, as evidenced by the absence of mortality, viral replication, and pathological lesions in immunized chickens. Collectively, these findings demonstrate that the recombinant HVT-H9-FAd is a promising bivalent vaccine candidate for controlling H9N2 AIV and FAdV-4 in poultry and provides an effective strategy for preventing co-circulating pathogens in chicken flocks.
2026-09-09 | Highly efficient intranasal H5N1 vaccine based on a safe vesicular stomatitis virus (VSV) vector.
Recombinant vesicular stomatitis virus (rVSV) is an increasingly popular vaccine vector, but it still faces challenges such as difficulties in construction, low in vitro amplification titers, safety concerns, and uncertain mucosal immune effects. Therefore, there is an urgent need to construct new VSV vectors for next-generation vaccines with high immunogenicity and excellent safety. In this study, we independently constructed a high-expression 6-9G recombinant replication-competent VSV vector. Based on the 6-9G vector, site-directed mutations were introduced into the M gene, including deletion of the 51st amino acid (Δ51), Δ51 + V221F, and Δ51 + S226R, to generate vectors designated as 6-9G-Δ51, 6-9G-Δ51 + V221F, and 6-9G-Δ51 + S226R. Through in vitro replication kinetics and in vivo immunogenicity studies, we identified 6-9G-Δ51 + S226R vector with a favorable safety profile and strong immunogenicity. The highly pathogenic avian influenza virus H5 subtype clade 2.3.4.4b poses a global pandemic threat, urgently necessitating new strategies for its prevention and control. Based on the 6-9G-Δ51 + S226R vector, we constructed the 6-9ΔGΔ51+S226R-H5N1 influenza virus vectored vaccine by replacing the VSV-G gene with the HA and NA genes. This candidate demonstrated further improved safety while eliciting robust and durable humoral as well as mucosal immune responses after two doses, providing 100% protection in mice against lethal viral challenge. The successfully developed novel 6-9ΔGΔ51+S226R-H5N1 vaccine candidate not only exhibits excellent safety and immunogenicity but also represents a powerful potential tool for the effective prevention and control of highly pathogenic avian influenza.
2026-09-04 | Safety, humoral and cellular immune responses to a pre-pandemic adjuvanted influenza A (H5N8) vaccine.
Highly pathogenic avian influenza (HPAI) A(H5) viruses can be transmitted from infected birds to various mammalian species, including humans. Avian influenza viruses (AIVs), members of the Orthomyxoviridae family, possess segmented RNA genomes prone to reassortment, favoring the emergence of novel genetic traits that may alter transmissibility, pathogenicity, and antigenicity. Although no sustained human-to-human transmission has been reported, the potential adaptation of these viruses poses a significant pandemic threat. This study aimed to evaluate the non-clinical safety, toxicity, and humoral immune responses induced by an adjuvanted H5 influenza vaccine in rats and rabbits, to support future clinical safety trials in humans. Male and female Wistar rats and New Zealand rabbits were observed for 14, 28, and 90 days after receiving two intramuscular doses of the H5N8 vaccine (15 μg HA/dose) formulated with the IB160 oil-in-water emulsion adjuvant. No systemic comorbidities, central nervous system alterations, or relevant clinical signs were observed. Hematological parameters remained within normal ranges, with total and differential leukocyte counts showing only minor fluctuations (<1% of total leukocytes). Mild biochemical variations in urea and hepatic transaminase levels were not correlated with histopathological alterations. The vaccine elicited a robust humoral response soon after immunization, with all groups reaching protective HAI-antibody titers. Although antibody levels declined over time, particularly in males, they remained significantly above baseline, indicating durable immunological memory. Furthermore, the vaccine induced a specific cellular immune response, confirmed by IL-2 and TNF production by antigen-specific T lymphocytes in splenic cell cultures after the booster dose. In conclusion, the H5N8 vaccine with the IB160 adjuvant was well tolerated locally and systemically, without compromising vital organ function. The safety and immunogenicity findings are consistent with expectations for adjuvanted influenza vaccines, demonstrating strong and durable humoral and cellular immune responses.
proteins
2026-09-22 | Interaction between DEAD-box RNA helicase 10 and influenza PB1 polymerase selectively regulates influenza A virus replication.
Identifying the host factors that mediate avian influenza virus adaptation in mammals is important for monitoring zoonotic potential. Although viral polymerase adaptations are known to influence cross-species transmission, the engagement of specific host factors with divergent viral polymerases remains to be explored. We examined human DEAD-box RNA helicases (DDXs) as potential regulators of influenza polymerase activity. A screen of 16 DDXs identified DDX10 as a factor that selectively enhanced the polymerase activity and replication of human-adapted H1N1 viruses, including the 2009 pandemic strain, but not avian-origin H9N2 viruses. This differential activity was associated with DDX10 showing stronger interaction with human-origin PB1 (Cal04/H1N1) than with avian-origin PB1 (BJ16/H9N2). Strain specificity was mediated by two residues (336 and 364) within the PB1 catalytic domain: introducing H1N1-type residues (I336 and I364) into H9N2-PB1 conferred DDX10 responsiveness, while reciprocal mutations in H1N1-PB1 abolished it. This work defines DDX10 as a potential host factor that differentially supports influenza polymerase activity, revealing a specific molecular interface that contributes to the replication efficiency of distinct viral subtypes in human cells and providing insight into host-adaptive mechanisms. This study identifies DDX10 as a strain-specific host factor that differentially regulates influenza A virus replication. By demonstrating that DDX10 selectively enhances human-adapted H1N1 viruses over avian-origin H9N2 viruses through direct interaction with the viral PB1 protein, and by mapping two critical residues (positions 336 and 364) in PB1 that govern this selectivity, our work provides a mechanistic framework for understanding how a single host factor can modulate viral fitness and host adaptation. These findings have important implications for predicting cross-species transmission potential and may guide the development of host-targeted antiviral strategies.
2026-08-21 | Computational insights into the inhibitory potential of cyclotides Psyle B and Psyle C against key surface proteins of avian influenza H5N1.
Avian influenza viruses (AIVs) are RNA viruses endemic to wild birds, with highly pathogenic strains such as H5N1 causing major outbreaks. Hemagglutinin (HA) and neuraminidase (NA) proteins are key mediators of viral entry and spread. Cyclotides, plant-derived peptides with stable structures and potent bioactivity, have emerged as novel antiviral candidates. This study explored cyclotide-based drug design against H5N1 using computational approaches. HA and NA protein sequences were retrieved from NCBI and their physicochemical properties analyzed using ProtParam. Cyclotides from CyBase were modeled and refined in PyMOL, followed by molecular docking via ClusPro. Binding energies were further assessed with molecular mechanics generalized born surface area, while toxicity was predicted using ToxinPred. Molecular dynamics simulations supported the stability analyses. Results revealed that Psyle B and Psyle C exhibited strong interactions with HA and NA. Psyle B achieved a docking score of -1001.3 kcal/mol, and Psyle C -1031.6 kcal/mol, both predicted as non-toxic. These findings highlight Psyle B and Psyle C as promising antiviral leads. Nonetheless, in vitro and in vivo validation remains essential to confirm their therapeutic potential.
2026-08-13 | Identification and characterization of PB2 mutations associated with mammalian adaptation of highly pathogenic H5N1 avian influenza viruses.
The highly pathogenic avian influenza virus (HPAIV) subtype H5N1 has been continuously circulating among wild bird populations and domestic poultry. It's ongoing circulation has led to outbreaks in poultry and U.S. dairy cattle populations, as well as sporadic severe infections in individuals engaged in poultry and dairy farming. These occurrences have raised concerns about the potential evolution of this virus into a pandemic strain. To elucidate the molecular determinants facilitating H5N1 cross-species adaptation and to evaluate its implications for public health, we conducted serials of sequence analysis and specific-site mutations on the viral polymerase subunit PB2 to determine its effect on polymerase activity and viral infectivity. The results showed that three mutations in the PB2 protein (E362G, D441N and M631L) were presented cooperative effects associated with enhanced viral replication in mammalian cells. Compared to the original isolated strain of the 2.3.4.4b clade, A/chicken/NL/FAV-0033/2021, these three mutations were predominantly identified in isolates obtained from cattle and other mammalian hosts between 2021 and 2024. The M631L mutation, identified as the primary determinant of increased polymerase activity in mammalian cells, significantly enhanced the binding affinity of PB2 to ANP32A. The mutation E362G and D441N did not increased polymerase activity and viral replication significantly but enhanced binding affinity of PB2 to ANP32A. The combined mutations with E362G, D441N and M631L resulted in a significantly increased polymerase activity and viral replication in H5N1 virus, and significantly elevated viral loads and aggravated pulmonary pathology in lungs of mice with H5N1 infection. These findings indicate that the PB2-M631L mutation constitutes a crucial molecular marker for the adaptation of H5N1 to mammalian hosts, whereas the E362G and D441N mutations likely function as supportive modulatory factors that optimize this host-adaptation process.
2026-08-11 | Identification and functional characterization of a novel antiviral chicken interferon-υ.
Interferons are critical mediators of antiviral immunity in vertebrates. While type IV interferon (IFN-υ) has been identified in fish and amphibians, its existence and function in chickens remained unknown. Through systematic genomic screening, we identified and cloned a novel chicken interferon gene, designated ChIFN-υ. Phylogenetic analysis placed ChIFN-υ within a distinct clade alongside zebrafish and clawed frog IFN-υ, confirming its identity as a type IV interferon, with minimal homology to classical type I, II, or III IFNs. Expression profiling revealed constitutive ChIFN-υ expression in mucosal and immune tissues of healthy chickens, exhibiting a distinct developmental shift: highest in trachea and small intestine in 1-day-old chicks, shifting to spleen and lung in 4-week-old chickens. ChIFN-υ expression was strongly upregulated following H9N2 AIV infection. Functionally, recombinant ChIFN-υ protein activated the interferon-stimulated response element (ISRE) and Mx promoter in a dose-dependent manner and significantly inhibited the replication of both vesicular stomatitis virus (VSV) and H9N2 AIV in DF-1 cells. In vivo, early treatment with exogenous ChIFN-υ significantly reduced pulmonary and tracheal viral loads and decreased oropharyngeal and cloacal virus shedding in H9N2-infected chickens. In conclusion, this study identifies and functionally characterizes the type IV interferon in chickens, elucidating the evolutionary status, regulated expression, and antiviral efficacy of ChIFN-υ. These findings highlight its potential as a candidate for developing interferon-based therapies against avian viral diseases.
2026-06-26 | Avian Foxp3 acts as a switch for IL-10 by directly binding the T3G motif: revealing a novel epigenetic modulation paradigm.
Foxp3 is the master transcription factor for regulatory T (Treg) cell differentiation and function, essential for immune homeostasis and tolerance. While its role is well-characterized in mammals, its functional mechanisms in avian species remain poorly understood. We conducted comparative genomic and functional analyses of chicken Foxp3 (chFoxp3). DNA-binding specificity was determined using motif analysis and genome-wide scanning. An H9N2 avian influenza challenge model was used to assess Foxp3 expression dynamics and CD4⁺CD25⁺ T cell frequency in vivo. The transcriptional regulation of IL-10 by chFoxp3 was investigated through promoter binding and transactivation assays, with key domains mapped via mutagenesis. Avian Foxp3 has evolved independently from its mammalian ortholog. Unlike human Foxp3, which binds the FKHM motif, chFoxp3 specifically recognizes a T3G microsatellite motif. Genome-wide scanning identified potential targets enriched in the FoxO signaling pathway, including IL-10. In an H9N2 infection model, Foxp3 expression and CD4⁺CD25⁺ T cell frequency exhibited biphasic dynamics. Mechanistically, chFoxp3, but not human FoxP3, directly binds the T3G motif in the IL-10 promoter to activate transcription. This transactivation function critically depends on the HNT linker within its Fork-head domain. Our study reveals a novel mode of transcriptional regulation by chFoxp3 via T3G motif recognition, underscoring its functional diversification during evolution. These findings provide a foundation for understanding immune regulation in birds under both physiological and pathological conditions, such as avian influenza infection.
other
2026-09-07 | Transcriptome screening identifies circRNA-INSR as a novel host factor associated with avian influenza virus replication.
Circular RNAs (circRNAs) represent a class of covalently closed non-coding RNA molecules that exert vital regulatory effects on host-pathogen interplay. The H9N2 subtype of avian influenza virus (AIV) is a widespread pathogen on a global scale, inflicting considerable economic damage to the poultry sector and harboring potential risks of cross-species transmission to humans. Despite growing evidence suggesting that non-coding RNAs can modulate the replication of influenza viruses, the expression patterns and functions of avian-derived circRNAs during H9N2 AIV infection have been largely unclear. Here, we conducted a systematic investigation into the expression dynamics of circRNAs in DF1 cells infected with H9N2 AIV by high-throughput RNA sequencing technology. A total of 139 differentially expressed circRNAs were identified, with 58 exhibiting upregulation and 81 showing downregulation relative to non-infected control cells. Of note, a circRNA originating from exon 2 of the insulin receptor (INSR) gene displayed consistent upregulation during viral infection. Functional assays verified its contributing role in the replication of H9N2 AIV. Specifically, siRNA-mediated knockdown of circ-INSR significantly suppressed H9N2 AIV replication. This study is the first to identify circ-INSR as a host factor contributing to influenza virus replication. Our results provide a basis for developing circRNA-based strategies against H9N2 avian influenza virus.
2026-09-03 | A Rationally Designed Split Lettuce Aptamer Based on Large-Scale Mutational Analysis.
Split-aptamer biosensors offer exceptionally low background by assembling only in the presence of a target analyte; however, their performance is frequently limited by the lack of robust design rules for selecting effective split sites. Existing approaches largely rely on heuristic, structure-based assumptions that are poorly validated and often yield suboptimal signal. Herein, we introduce a systematic, data-driven strategy for identifying high-performance split sites within fluorogenic DNA aptamers. Using our massively parallel aptamer performance analyzer platform, we performed comprehensive single- and double-mutant analysis of the DFAME-binding region of the fluorogenic DNA aptamer Lettuce, informed by its three-dimensional structure. Dimensionality reduction and clustering of the resulting sequence-function landscape revealed mutation-tolerant elements within the binding domain that are suitable for splitting while preserving fluorophore activation. Sensors constructed using these nonintuitive split sites, which are unconventional by standard design principles, exhibited a nearly four-fold improvement in the fluorescence signal-to-background ratio for SARS-CoV-2 RNA detection compared to a prior split-Lettuce design. The same split architecture also enabled robust detection of high-pathogenicity H5Nx avian influenza RNA. These results demonstrate that large-scale, data-driven interrogation of aptamer sequence-function relationships can identify nonintuitive split sites and provide a proof-of-concept framework for developing measurement-based design principles for split-aptamer biosensors.
2026-07-30 | Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice.
Self-amplifying mRNA (samRNA) vaccines can induce potent immune responses at lower doses than conventional non-replicating mRNA vaccines; however, large RNA size and manufacturing considerations associated with 5' capping remain important challenges. Here, we developed a capless samRNA (CLsamRNA) vaccine platform derived from a Coxsackievirus B5 replicon that uses internal ribosome entry site-mediated cap-independent translation. Systematic optimization of key genetic elements enhanced antigen expression from the CLsamRNA backbone. Using reporter RNAs, LNP-formulated CLsamRNA showed rapid early expression and RNA amplification, with expression kinetics distinct from VEEV-based saRNA and nucleoside-modified mRNA comparators. When encoding the hemagglutinin antigen of highly pathogenic avian influenza clade 2.3.4.4 H5 viruses, CLsamRNA induced potent immune responses after LNP formulation. In mouse models, CLsamRNA induced potent neutralizing antibody responses, cross-reactive activity against clade 2.3.4.4b H5N1 virus, Th1-skewed humoral immunity, and strong antigen-specific cellular immune responses. CLsamRNA also elicited platform-specific early inflammatory and lymph node immune gene signatures associated with antigen presentation, costimulation, and cellular immune priming. Notably, a minimal 0.01-μg dose of CLsamRNA conferred complete protection against lethal H5N8 influenza virus challenge in BALB/c mice. These findings support CLsamRNA as a distinct cap-independent RNA vaccine platform with dose-sparing protective efficacy against highly pathogenic avian influenza H5 viruses.
2026-07-17 | Characterization of bovine-derived H5N1 viruses expressing fluorescent and luminescent reporter proteins.
Highly pathogenic avian influenza H5N1 clade 2.3.4.4b viruses present a broad host range, with recent spillover and sustained transmission in dairy cattle reported in the USA. Replication-competent reporter viruses are critical tools that enable real-time monitoring of virus replication, facilitating high-throughput screens. In this study, we engineered three recombinant H5N1 clade 2.3.4.4b reporter viruses expressing nanoluciferase (NLuc) and two fluorescent reporter proteins, miniGFP2 and UnaG within the open reading frame of the nonstructural gene of the bovine A/Cattle/Texas/063224-24-1/2024 (TX2/24) virus. All reporter viruses replicated efficiently in vitro, presenting replication kinetics comparable to the parental rTX2/24 virus, but exhibited smaller plaque sizes, suggesting reduced cell-to-cell spread. In vivo infection studies in mice showed comparable pathogenicity among all four viruses, although rTX2/24-miniGFP2 and rTX2/24-UnaG exhibited decreased virus shedding relative to rTX2/24 and rTX2/24-NLuc. Virus titrations and in situ localization of virus replication sites demonstrated robust replication in respiratory tissues, with slightly attenuated systemic dissemination of all three reporter viruses. Fluorescent virus neutralization assays using miniGFP2 and UnaG reporter viruses accurately quantified neutralizing antibody titres in sera from naturally infected dairy cattle, consistent with wild-type virus assays. Additionally, the utility of the NLuc reporter virus for antiviral screening was validated against oseltamivir in vitro. Collectively, these results establish the H5N1 TX2/24-based reporter viruses as versatile and biologically relevant tools for investigating H5N1 pathogenesis and for use in serological and antiviral drug screens.
2026-07-09 | Characterization of oseltamivir-resistant A(H5N1) clade 2.3.4.4b, genotype D1.1 variants identified in poultry farms of British Columbia, Canada.
Highly pathogenic avian influenza A(H5N1) viruses of clade 2.3.4.4b, genotype D1.1, are responsible for widespread outbreaks in poultry and continue to cause sporadic, sometimes severe, human infections. Herein, we characterized a wild-type (WT) influenza A(H5N1) D1.1 isolate (BC-H5N1-WT) and its H275Y neuraminidase (NA) variant (BC-H5N1-H275Y), both of which emerged on farms in British Columbia, Canada, during the fall 2024 outbreak. In vitro analysis assessed replication kinetics in MDCK cells, with supernatants collected at different days post-infection (p.i.) and titrated by TCID50 and qRT-PCR. Neuraminidase inhibitor (NAI) susceptibility was determined by NA inhibition assays, whereas susceptibility to baloxavir acid (BXA) was evaluated by plaque reduction assay. In vivo virulence was evaluated in BALB/c mice infected with serial 10-fold dilutions of each virus to monitor weight loss and mortality. Viral titers in lungs, brain, nose, kidney, spleen, and heart were quantified at day 4 p.i. The BC-H5N1-WT virus was susceptible to the four antivirals tested, whereas BC-H5N1-H275Y displayed resistance to oseltamivir and peramivir but remained susceptible to zanamivir and BXA. The BC-H5N1-WT exhibited significantly higher viral replication titers than BC-H5N1-H275Y at all tested time points and showed larger plaque sizes. In mice, BC-H5N1-WT was more virulent with LD50 values of 1.78 × 103 PFUs compared to 8.71 × 104 PFUs for BC-H5N1-H275Y, and produced higher viral titers in lungs and other organs. Despite the reduced fitness of the resistant H5N1 D1.1 variant, its emergence in the absence of viral selection pressure underscores the need for continued surveillance.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Avian influenza.
1 orphan drug designation for Avian influenza.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
Anti-H5N1 equine immunoglobulin F(ab')2 fragments | antibodies | EMA | Fab'entech |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.